157 related articles for article (PubMed ID: 14551292)
41. Prognostic significance of microsatellite instability in sporadic mucinous colorectal cancers.
Messerini L; Ciantelli M; Baglioni S; Palomba A; Zampi G; Papi L
Hum Pathol; 1999 Jun; 30(6):629-34. PubMed ID: 10374769
[TBL] [Abstract][Full Text] [Related]
42. [Prognostic contribution and therapeutic implications of microsatellite instability in colorectal cancer. Role of the pathologist].
Chenard MP
Ann Pathol; 2000; 20 Suppl():S94-6. PubMed ID: 11261313
[No Abstract] [Full Text] [Related]
43. Detection of vimentin (VIM) methylation in the serum of colorectal cancer patients.
Shirahata A; Sakuraba K; Goto T; Saito M; Ishibashi K; Kigawa G; Nemoto H; Hibi K
Anticancer Res; 2010 Dec; 30(12):5015-8. PubMed ID: 21187483
[TBL] [Abstract][Full Text] [Related]
44. Microsatellite instability as a molecular marker for very good survival in colorectal cancer patients receiving adjuvant chemotherapy.
Elsaleh H; Shannon B; Iacopetta B
Gastroenterology; 2001 Apr; 120(5):1309-10. PubMed ID: 11288748
[No Abstract] [Full Text] [Related]
45. Clinical significance of prognostic and predictive markers in colorectal cancer.
Longley DB; McDermott U; Johnston PG
Pharmacogenomics J; 2002; 2(4):209-16. PubMed ID: 12196910
[No Abstract] [Full Text] [Related]
46. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer.
Gryfe R; Kim H; Hsieh ET; Aronson MD; Holowaty EJ; Bull SB; Redston M; Gallinger S
N Engl J Med; 2000 Jan; 342(2):69-77. PubMed ID: 10631274
[TBL] [Abstract][Full Text] [Related]
47. The relationship between genetic profiling, clinicopathological factors and survival in patients undergoing surgery for node-negative colorectal cancer: 10-year follow-up.
Powell AG; Ferguson J; Al-Mulla F; Orange C; McMillan DC; Horgan PG; Edwards J; Going JJ
J Cancer Res Clin Oncol; 2013 Dec; 139(12):2013-20. PubMed ID: 24072233
[TBL] [Abstract][Full Text] [Related]
48. Genetic Variants in the Regulatory T cell-Related Pathway and Colorectal Cancer Prognosis.
Neumeyer S; Hua X; Seibold P; Jansen L; Benner A; Burwinkel B; Halama N; Berndt SI; Phipps AI; Sakoda LC; Schoen RE; Slattery ML; Chan AT; Gala M; Joshi AD; Ogino S; Song M; Herpel E; Bläker H; Kloor M; Scherer D; Ulrich A; Ulrich CM; Win AK; Figueiredo JC; Hopper JL; Macrae F; Milne RL; Giles GG; Buchanan DD; Peters U; Hoffmeister M; Brenner H; Newcomb PA; Chang-Claude J
Cancer Epidemiol Biomarkers Prev; 2020 Dec; 29(12):2719-2728. PubMed ID: 33008876
[TBL] [Abstract][Full Text] [Related]
49. Aberrant DNA methylation: have we entered the era of more than one type of colorectal cancer?
Iacopetta B
Am J Pathol; 2003 Apr; 162(4):1043-5. PubMed ID: 12651596
[No Abstract] [Full Text] [Related]
50. Tumour site, sex, and survival in colorectal cancer.
Buyse M; Piedbois Y; Piedbois P; Gray R
Lancet; 2000 Sep; 356(9232):858. PubMed ID: 11022959
[No Abstract] [Full Text] [Related]
51. Microsatellite instability in colorectal cancer: prognostic, predictive or both?
van Rijnsoever M; Elsaleh H; Iacopetta B
Am J Pathol; 2002 Jan; 160(1):384-5; author reply 385-6. PubMed ID: 11786433
[No Abstract] [Full Text] [Related]
52. A complex microsatellite at chromosome 7q33 as a new prognostic marker of colorectal cancer.
Ye X; Deng H; Su M; Liao Q; Huang D; Liao DF; Xiao ZQ; Cao D
Oncotarget; 2017 Oct; 8(51):88760-88769. PubMed ID: 29179473
[TBL] [Abstract][Full Text] [Related]
53. [Colorectal cancer: at the crossroads of histopathology and molecular pathology].
Risio M
Tumori; 2001; 87(1 Suppl 1):S75. PubMed ID: 11300034
[No Abstract] [Full Text] [Related]
54. Assessing the ProMCol classifier as a prognostic marker for non-metastatic colorectal cancer within the Melbourne Collaborative Cohort Study.
Joo JE; Jayasekara H; Wong EM; Clendenning M; Rosty C; Winship IM; Jenkins MA; Hopper JL; English DR; Milne RL; Giles GG; Southey MC; Buchanan DD
Gut; 2019 Apr; 68(4):761-762. PubMed ID: 29574407
[No Abstract] [Full Text] [Related]
55. Rethinking colorectal cancer prognosis: beyond microsatellite status.
Fenocchio E
Lancet Gastroenterol Hepatol; 2024 Jul; 9(7):585-586. PubMed ID: 38734025
[No Abstract] [Full Text] [Related]
56. CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels.
Lee S; Cho NY; Yoo EJ; Kim JH; Kang GH
Arch Pathol Lab Med; 2008 Oct; 132(10):1657-65. PubMed ID: 18834226
[TBL] [Abstract][Full Text] [Related]
57. Quantitative detection of promoter hypermethylation in multiple genes in the serum of patients with colorectal cancer.
Leung WK; To KF; Man EP; Chan MW; Bai AH; Hui AJ; Chan FK; Sung JJ
Am J Gastroenterol; 2005 Oct; 100(10):2274-9. PubMed ID: 16181380
[TBL] [Abstract][Full Text] [Related]
58. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases.
Barault L; Charon-Barra C; Jooste V; de la Vega MF; Martin L; Roignot P; Rat P; Bouvier AM; Laurent-Puig P; Faivre J; Chapusot C; Piard F
Cancer Res; 2008 Oct; 68(20):8541-6. PubMed ID: 18922929
[TBL] [Abstract][Full Text] [Related]
59. Meta-Analysis of the Prognostic and Predictive Role of the CpG Island Methylator Phenotype in Colorectal Cancer.
Wang J; Deng Z; Lang X; Jiang J; Xie K; Lu S; Hu Q; Huo Y; Xiong X; Zhu N; Zhang W
Dis Markers; 2022; 2022():4254862. PubMed ID: 36157209
[TBL] [Abstract][Full Text] [Related]
60. Effect of DNA methylation status on first-line anti-epidermal growth factor receptor treatment in patients with metastatic colorectal cancer.
Osumi H; Ouchi K; Shinozaki E; Takahashi S; Ooki A; Nakayama I; Wakatsuki T; Ogura M; Takahari D; Chin K; Yamaguchi K; Ishioka C
Int J Colorectal Dis; 2022 Jun; 37(6):1439-1447. PubMed ID: 35612620
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
